AbbVie Shares Slide 6.5% Despite Strong Revenue Growth and 2026 Expansion Plans
AbbVie (ABBV) stock tumbled 6.52% to $210.89, erasing early gains despite reporting robust full-year revenue of $61.16 billion—an 8.6% year-over-year increase. The market's negative reaction overshadowed strong performance in immunology, neuroscience, and oncology segments, with Skyrizi leading the immunology portfolio at $30.4 billion in global revenue.
Investors appeared unconvinced by the company's 2026 outlook, even as Rinvoq expanded its market share and AbbVie emphasized portfolio diversification. The decline reflects broader skepticism about pharmaceutical growth trajectories amid shifting healthcare landscapes.